Evidence map›Paper›PMID 35880162›Full record

ArticleFrontiers in oncology2022

Inhibition of Osteoblast Differentiation by JAK2

Aikaterini Karagianni, Shinobu Matsuura, Louis C Gerstenfeld, Katya Ravid

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Aikaterini KaragianniDepartment of Internal Medicine, University of Crete, School of Medicine, Heraklion, Greece.
Shinobu MatsuuraDepartment of Medicine, Whitaker Cardiovascular Research Institute, Boston University School of Medicine, Boston, MA, United States.
Louis C GerstenfeldDepartment of Orthopaedic Surgery, Boston University School of Medicine, Boston, MA, United States.
Katya RavidDepartment of Medicine, Whitaker Cardiovascular Research Institute, Boston University School of Medicine, Boston, MA, United States.
Boston University · USUniversity of Crete · GR

Funding

A path to thrombosis in primary myelofibrosisR01HL136363 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2018 to 2021
$1.9M
Megakaryocyte Mechanosensing Toward Platelet BiogenesisR01HL158670 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2021 to 2024
$1.6M
The bone marrow extracellular matrix: scaffold of hematopoiesisK01OD025290 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MATSUURA, SHINOBU · 2019 to 2023
$611k
NHLBI NIH HHS R01 HL136363NHLBI NIH HHS R01 HL158670NIH HHS K01 OD025290
6 · The paper itself

Abstract

Past studies described interactions between normal megakaryocytes, the platelet precursors, and bone cell precursors in the bone marrow. This relationship has also been studied in context of various mutations associated with increased number of megakaryocytes. The current study is the first to examine the effects of megakaryocytes from transgenic mice carrying the most common mutation that causes primary myelofibrosis (PMF) in humans (JAK2

Indexed as

boneJAK2megakaryocytemouseosteoblastosteosclerosisprimary myelofibrosis

Identifiers

PMID35880162
PMCPMC9307716
OpenAlexW4284885870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.